Glycemic variability indices can be used to diagnose islet transplantation success in type 1 diabetic patients
- 44 Downloads
High glycemic variability (GV) is the major indication for islet transplantation (IT) in patients with type 1 diabetes (T1D). The actual criteria used to assess graft function do not consider GV improvement. Our study aimed to describe GV indices’ evolution in T1D patients who benefited from IT during the TRIMECO trial and to evaluate if thresholds might be defined to diagnose IT success.
We collected data from 29 patients of the TRIMECO trial, a clinical trial (NCT01148680) comparing the metabolic efficacy of IT with intensive insulin therapy. Based on CGM data, we analyzed mean glucose level and four GV indices (standard deviation, coefficient of variation, MAGE and GVP) before (M0) and 6 months (M6) after IT.
Each GV index decreased significantly between M0 and M6: SD 53.9 mg/dL [44.6–61.5] versus 20.1 mg/dL [13.5–24.3]; CV 35.2% [30.6–37.7] versus 17.3% [12.0–20.5]; MAGE 134.9 mg/dl [111.2–155.8] versus 51.9 mg/dL [32.4–62.4]; GVP 35.3% [24.9–47.2] versus 12.2% [6.2–18.8] (p ≤ 0.0001). Thresholds diagnosing IT success at 6 months post-transplant were an SD at 22.76 mg/dL (sensibility 88.89%, specificity 80.00%), a CV at 17.47% (sensibility 88.89%, specificity 70.00%), a MAGE at 54.81 mg/dL (sensibility 88.89%, specificity 80.00%) and a GVP at 12.27% (sensibility 88.89%, specificity 70.00%).
This study confirms a positive impact of IT on GV. The proposed thresholds allow an easy evaluation of IT success using only CGM data and may be a clinical tool for the follow-up of transplanted patients.
KeywordsGlycemic variability Islet transplantation Continuous glucose monitoring Brittle diabetes
Continuous glucose monitoring
Coefficient of variation
Glycemic variability percentage
Mean amplitude glycemic excursion
- ROC curve
Receiver operating characteristic curve
Type 1 diabetes
Time in range
This work was supported by a Research Year Scholarship from Grenoble Alpes University.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The institutional review board approved the study (French Committee for the Protection of Persons participating in biomedical research “Sud-Est V”; no 09-CHUG-21) and Clinical Trial Authorization was obtained from the French National Competent Authority (ANSM-no 2008-A01554-51).
Informed consent was obtained from the patients included in this study.
- 11.Wojtusciszyn A, Branchereau J, Esposito L, et al (2019) Indications for islet or pancreatic transplantation: statement of the TREPID working group on behalf of the Société francophone du diabète (SFD), Société francaise d’endocrinologie (SFE), Société francophone de transplantation (SFT) and Société française de néphrologie-dialyse-transplantation (SFNDT). Diabetes Metab 45(3):224–237PubMedCrossRefGoogle Scholar
- 12.CITR 9th annual report | CITR [Internet]. [cited 2018 May 2]. Available from: https://citregistry.org/content/citr-9th-annual-report. Accessed 2 May 2018
- 13.Lablanche S, Vantyghem M-C, Kessler L et al (2018) Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 6(7):527–537PubMedCrossRefGoogle Scholar
- 21.Vantyghem M-C, Raverdy V, Balavoine A-S et al (2012) Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3). J Clin Endocrinol Metab 97(11):E2078–E2083PubMedCrossRefGoogle Scholar
- 25.Geiger MC, Ferreira JV, Hafiz MM et al (2005) Evaluation of metabolic control using a continuous subcutaneous glucose monitoring system in patients with type 1 diabetes mellitus who achieved insulin independence after islet cell transplantation. Cell Transplant 14(2–3):77–84PubMedCrossRefGoogle Scholar
- 26.Zhou J, Li H, Ran X et al (2011) Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring. Med Sci Monit Int Med J Exp Clin Res 17(1):CR9–CR13Google Scholar
- 27.Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR (2011) Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther 13(9):921–928PubMedPubMedCentralCrossRefGoogle Scholar
- 33.Hanefeld M, Koehler C, Hoffmann C, Wilhelm K, Kamke W, Gerstein H (2010) Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. Diabet Med J Br Diabet Assoc 27(2):175–180CrossRefGoogle Scholar
- 35.Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Fox LA, Beck RW, Xing D (2010) Variation of interstitial glucose measurements assessed by continuous glucose monitors in healthy, nondiabetic individuals. Diabetes Care 33(6):1297–1299PubMedCentralCrossRefGoogle Scholar